Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Yinting Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0490-5216; OpenAlex author ID A5028211712. Sources: OpenAlex.

Their work

Papers
21 (first author 2, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 21

  1. KRAS/ACTN4/p65-NR2A axis mediates glutamine-glutamate metabolic coupling between schwann cells and pancreatic cancer promoting perineural invasion. Last author DOI 10.1016/j.jare.2025.10.030↗
  2. Extracellular Vesicle-Packaged Linc-ZNF25-1 from Pancreatic Cancer Cell Promotes Pancreatic Stellate Cell Uptake of Asparagine to Advance Chemoresistance. Last author DOI 10.1002/advs.202413439↗
  3. Correction: Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer. Last author DOI 10.1039/d5nr90172c↗
  4. Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer. Last author DOI 10.1007/s00280-023-04616-6↗
  5. Identification of gemcitabine resistance-related AHNAK2 gene associated with prognosis and immune infiltration in pancreatic cancer. Last author DOI 10.1016/j.heliyon.2024.e33687↗
  6. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis. Last author DOI 10.1016/j.trsl.2022.11.007↗
  7. TIMP1 derived from pancreatic cancer cells stimulates Schwann cells and promotes the occurrence of perineural invasion. Last author DOI 10.1016/j.canlet.2022.215863↗
  8. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. Last author DOI 10.1016/j.bcp.2020.114085↗
  9. Peripheral blood monocytes predict clinical prognosis and support tumor invasiveness through NF-κB-dependent upregulation of Snail in pancreatic cancer. Co-author DOI 10.21037/tcr-21-980↗
  10. Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer. Co-author DOI 10.3389/fgene.2021.632803↗
  11. Development and validation of a novel nomogram for pretreatment prediction of liver metastasis in pancreatic cancer. Last author DOI 10.1002/cam4.2930↗
  12. Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer. Last author DOI 10.1039/c9nr04976b↗
  13. MicroRNA hsa-miR-623 directly suppresses MMP1 and attenuates IL-8-induced metastasis in pancreatic cancer. Co-author DOI 10.3892/ijo.2019.4803↗
  14. Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8. Co-author DOI 10.1002/cam4.1824↗
  15. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer. Last author DOI 10.1002/ijc.31248↗
  16. MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells. Co-author DOI 10.7150/thno.24281↗
  17. New developments in the early diagnosis of pancreatic cancer. Co-author DOI 10.1080/17474124.2017.1271323↗
  18. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy. First author DOI 10.1111/cas.13267↗
  19. Pancreatic Cancer Epidemiology, Detection, and Management. Co-author DOI 10.1155/2016/8962321↗
  20. A Nanoparticle Carrier for Co-Delivery of Gemcitabine and Small Interfering RNA in Pancreatic Cancer Therapy. First author DOI 10.1166/jbn.2016.2269↗
  21. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic can… Co-author DOI 10.1016/j.nano.2013.08.007↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kaihong Huang · 15 shared papers, 2014–2025 · strength 1.54
  2. Guoda Lian · 13 shared papers, 2016–2025 · strength 1.35
  3. Yaqing Li · 11 shared papers, 2016–2025 · strength 1.23
  4. Zhenfeng Tian · 5 shared papers, 2021–2026 · strength 1.09
  5. Shangxiang Chen · 7 shared papers, 2020–2025 · strength 1.02
  6. Linjuan Zeng · 11 shared papers, 2014–2025 · strength 0.99
  7. Guangsheng Ou · 4 shared papers, 2022–2024 · strength 0.82
  8. Jinmao Zou · 5 shared papers, 2020–2025 · strength 0.74
  9. Ying Tan · 4 shared papers, 2020–2024 · strength 0.65
  10. Miao Yu · 2 shared papers, 2025–2026 · strength 0.64
  11. Shaojie Chen · 7 shared papers, 2016–2021 · strength 0.62
  12. Xingyi Lin · 3 shared papers, 2022–2024 · strength 0.57
  13. Shaojie Chen · 3 shared papers, 2020–2025 · strength 0.48
  14. Jiajia Li · 5 shared papers, 2016–2021 · strength 0.48
  15. Jiajia Li · 3 shared papers, 2016–2025 · strength 0.40
  16. Chumei Huang · 5 shared papers, 2017–2019 · strength 0.38
  17. Kege Yang · 5 shared papers, 2016–2018 · strength 0.35
  18. Qiubo Zhang · 5 shared papers, 2014–2020 · strength 0.34
  19. Feifei Huang · 1 shared paper, 2021 · strength 0.14
  20. Yutong Chen · 1 shared paper, 2019 · strength 0.10
  21. Jian Li · 1 shared paper, 2018 · strength 0.07
  22. Hong Su · 1 shared paper, 2018 · strength 0.07
  23. Jiajia Li · 1 shared paper, 2017 · strength 0.06
  24. Yong Wang · 1 shared paper, 2014 · strength 0.04
  25. Xintao Shuai · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.